Latest quarter
AbbVie reported third-quarter revenue of $17.4 billion, up 10.3% from $15.8 billion a year earlier and 0.20% above the consensus. Adjusted earnings per share of $3.82 also beat the consensus estimate of $3.74. Diluted earnings per share were $2.38, compared with $0.10 a year earlier.
Skyrizi sales were $5.8 billion and Rinvoq sales were $2.7 billion. AbbVie’s filing attributed growth in both immunology medicines to market-share gains and market growth across their indications. Humira revenue fell to $683.0 million; the filing attributed its decline to biosimilar competition following loss of exclusivity.
Gross margin rose to 75.4% from 66.4%, while operating margin increased to 36.0% from 12.1%. The filing attributed the gross-margin increase partly to higher revenue relative to fixed costs, lower intangible-asset amortization and impairment charges in the prior-year quarter.
CFO Scott Reents said AbbVie generated approximately $14.0 billion in free cash flow in the first nine months of 2026, including nearly $2.7 billion of Skyrizi royalty payments.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $17.4 billion | $15.8 billion | 10.3% |
| Diluted EPS | $2.38 | $0.10 | 2,281.5% |
| Gross margin | 75.4% | 66.4% | 9.0 percentage points |
| Operating margin | 36.0% | 12.1% | 23.9 percentage points |
| Free cash flow | $3.1 billion | $4.9 billion | −36.2% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $3.82 | $3.74 | Beat by 2.14% |
| Revenue | $17.4 billion | $17.4 billion | In line |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
CEO Rob Michael said Skyrizi and Rinvoq continued to grow despite competition, including in inflammatory bowel disease. He pointed to U.S. approval of a Skyrizi injection option for induction treatment in Crohn’s disease and said the company had started trials combining Skyrizi with other mechanisms in Crohn’s and ulcerative colitis.
Asked about the Crohn’s launch, Chief Commercial Officer Jeff Stewart said AbbVie’s sales teams were already promoting the new dosing option. He expected access to take about 60 days or longer and anticipated market-share gains in the first part of the year into the second quarter. On payer negotiations for 2027, Stewart said a low-single-digit rebate concession remained a useful assumption for immunology and expected access for Rinvoq’s pending vitiligo and alopecia areata indications.
Stewart said AbbVie planned to expand its dermatology sales forces and invest in consumer outreach as it works to develop those markets. On Juvemo, its Parkinson’s treatment, he said initial demand exceeded expectations, but patients were enrolling or using medical exception processes because access was not yet available. Michael said the treatment’s sales ramp would be more significant in 2028 and beyond because of the timing of Medicare coverage.
CFO Scott Reents said third-quarter adjusted operating margin was 48.7% of sales, including a 1.2% unfavorable impact from acquired in-process research and development expense. He said the full-year and fourth-quarter earnings outlooks exclude such expenses that might be incurred after their respective guidance cutoffs.
On investment, Michael said the completed Apogee acquisition added dermatology and inflammatory-disease assets. He expected future deals to be more often bolt-on additions, with AbbVie focused on its core therapeutic areas and also looking to expand in obesity.
Guidance
CFO Scott Reents said AbbVie raised its 2026 revenue forecast by $200 million to approximately $67.8 billion and its adjusted earnings guidance by 11 cents at the midpoint to $13.95–$13.99 per share. The earnings outlook excludes acquired in-process research and development expense that may arise beyond the third quarter.
Reents said the increased immunology forecast of $34.9 billion includes higher expectations of $21.8 billion for Skyrizi and $10.3 billion for Rinvoq. AbbVie also raised its neuroscience forecast to approximately $13.0 billion and its oncology outlook to $6.6 billion, with higher expected Venclexta sales of $3.1 billion and lower Imbruvica sales of $2.1 billion.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| Revenue, Immunology | FY2027 | AbbVie expects robust immunology growth in FY2027. | — | — |
| Revenue | FY2027 | AbbVie expects top-tier sales growth in FY2027. | — | — |
| Dividend | Q1 FY2027 | $1.82 | — | New |
| EPS, non-GAAP | Q4 FY2026 | $3.83–$3.87 | — | New |
| Revenue | Q4 FY2026 | $18.4 billion | — | New |
| Operating margin, non-GAAP | FY2026 | 46.7% | — | New |
| Operating expenses, Non Gaap Sg&a | FY2026 | $14.5 billion | — | New |
| Research and development, non-GAAP | FY2026 | $9.8 billion | — | New |
| Gross margin, non-GAAP | FY2026 | 84.0% | — | New |
| Revenue, Botox Cosmetic | FY2026 | $2.8 billion | — | New |
| Revenue, Aesthetics | FY2026 | $5.0 billion | — | New |
| Revenue, Imbruvica | FY2026 | $2.1 billion | — | New |
| Revenue, Venclexta | FY2026 | $3.1 billion | — | New |
| Revenue, Oncology | FY2026 | $6.6 billion | — | New |
| Revenue, Vylev | FY2026 | $1.0 billion | — | New |
| Revenue, Oral Cgrp | FY2026 | $3.1 billion | — | New |
| Revenue, Botox Therapeutic | FY2026 | $4.2 billion | — | New |
| Revenue, Vraylar | FY2026 | $4.2 billion | — | New |
| Revenue, Neuroscience | FY2026 | $13.0 billion | — | New |
| Revenue, Rinvoq | FY2026 | $10.3 billion | — | New |
| Revenue, Skyrizi | FY2026 | $21.8 billion | — | New |
| Revenue, Immunology | FY2026 | $34.9 billion | — | New |
| Revenue | FY2026 | $67.8 billion | — | New |
| EPS, non-GAAP | FY2026 | $13.95–$13.99 | — | New |